Valuation: SpectraCure AB (publ)

Market Cap 22.42M 2.36M 2.05M 1.91M 1.75M 3.29M 225M 3.35M 8.8M 113M 8.87M 8.68M 376M P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value 11.69M 1.23M 1.07M 997K 911K 1.72M 117M 1.74M 4.59M 58.78M 4.63M 4.52M 196M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
28.39%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 54 2025-09-30
Director of Finance/CFO - 2026-05-31
Chief Tech/Sci/R&D Officer - 2025-10-06
Director TitleAgeSince
Director/Board Member 63 2012-08-30
Director/Board Member 72 2021-12-31
Chairman 74 2021-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.22%-5.14% - - 2.36M
-0.13%-1.39%+30.43%+51.51% 1.44B
+5.83%0.00%-35.20%-50.78% 284M
-0.91%+2.36%-10.77%-47.84% 53.74M
-9.43%-15.79%+9.09%-15.79% 50.92M
Average -2.04%-2.98%-1.61%-15.72% 457.43M
Weighted average by Cap. -2.11%-2.53%+18.42%+30.82%

Financials

2024 2025
Net sales - -
Net income -23M -2.42M -2.1M -1.96M -1.79M -3.38M -231M -3.43M -9.03M -116M -9.1M -8.9M -385M -56.08M -5.91M -5.12M -4.78M -4.37M -8.24M -564M -8.37M -22M -282M -22.19M -21.71M -939M
Net Debt -13.13M -1.38M -1.2M -1.12M -1.02M -1.93M -132M -1.96M -5.15M -66.02M -5.2M -5.08M -220M -10.74M -1.13M -979K -916K -837K -1.58M -108M -1.6M -4.21M -53.99M -4.25M -4.16M -180M
Logo SpectraCure AB (publ)
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
-